The original version of this article unfortunately included a mistake in Fig. 2b where the images of mice in the tumour control group (right), day 30 (bottom) should be removed as the wrong images (duplicate of day 17) were inserted by mistake. At this time point the tumour control mice were no longer alive and the images were replaced by black areas.
The revised Fig. 2 is placed on the following page.
Fig. 2
In vivo efficacy of transiently transfected T cells depends on route of administration. (a) NSG mice were injected i.p. with 106 HCT 116 ff-Luc 2 days before injection of T cells. T cell treated groups were treated on days 2, 4, 8, 11, and 16 with Radium-1 TCR or irrelevant TCR expressing T cells i.p. (n = 10). The Radium-1 TCR group was treated with 107 Radium-1 TCR electroporated T cells at each injection, the irrelevant TCR group (n = 10) was treated with 107 DMF5 TCR electroporated T cells at each injection i.p. Tumour control received no treatment (n = 4). Three mice from each group are shown. (b) Tumour load was evaluated by bioluminescence imaging on days 2, 9, 17, 23, and 30. Black areas indicate loss of mice. (c) Average tumour load (total flux photons/s) in the different groups are shown (p = 0.031 and 0.0089). (d) Survival time of the different treatment groups after tumour injection (p = 0.0072). The results shown are representative of three independent experiments. (e) Radium-1 Tc treated group (n = 5) and mock electroporated Tc treated group (n = 4) were treated with 107 T cells i.v. at indicated time points. The tumour control group (n = 3) was not given any treatment. (f) Tumour load was evaluated by bioluminescence imaging on days 2, 7, 17, and 29. (g) Average tumour load (total flux photons/s) in animals given T cells i.v. and control group, (h) Kaplan–Meier animals given T cells i.v. and control group
×
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.
Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
